413 related articles for article (PubMed ID: 31341124)
21. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
Earl DE; Loochtan AI; Bedlack RS
Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
[No Abstract] [Full Text] [Related]
22. Clinical features, diagnosis, and management of pembrolizumab-induced myasthenia gravis.
Zhao S; Zhou Y; Sun W; Li Z; Wang C
Clin Exp Immunol; 2023 Mar; 211(2):85-92. PubMed ID: 36426591
[TBL] [Abstract][Full Text] [Related]
23. Nivolumab-related myasthenia gravis with myositis requiring prolonged mechanical ventilation: a case report.
Saishu Y; Yoshida T; Seino Y; Nomura T
J Med Case Rep; 2022 Feb; 16(1):61. PubMed ID: 35152911
[TBL] [Abstract][Full Text] [Related]
24. [Immune checkpoint inhibitor-induced anti-striational antibodies in myasthenia gravis and myositis: a case report].
Sugiyama Y; Esa Y; Watanabe A; Kobayashi J; Suzuki S; Takahashi D
Rinsho Shinkeigaku; 2021 Sep; 61(9):630-634. PubMed ID: 34433744
[TBL] [Abstract][Full Text] [Related]
25. Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report.
Cham J; Ng D; Nicholson L
J Med Case Rep; 2021 May; 15(1):278. PubMed ID: 34053457
[TBL] [Abstract][Full Text] [Related]
26. A case of late-onset, thymoma-associated myasthenia gravis with ryanodine receptor and titin antibodies and concomitant granulomatous myositis.
Stefanou MI; Komorowski L; Kade S; Bornemann A; Ziemann U; Synofzik M
BMC Neurol; 2016 Sep; 16(1):172. PubMed ID: 27623618
[TBL] [Abstract][Full Text] [Related]
27. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
Nguyen BH; Kuo J; Budiman A; Christie H; Ali S
Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019
[TBL] [Abstract][Full Text] [Related]
28. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review.
Chen JH; Lee KY; Hu CJ; Chung CC
Medicine (Baltimore); 2017 Dec; 96(50):e9262. PubMed ID: 29390370
[TBL] [Abstract][Full Text] [Related]
29. Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune-Biological Evaluation and Case Report.
Botta C; Agostino RM; Dattola V; Cianci V; Calandruccio ND; Bianco G; Mafodda A; Maisano R; Iuliano E; Orizzonte G; Mazzacuva D; Falzea AC; Saladino RE; Giannicola R; Restifo G; Aguglia U; Caraglia M; Correale P
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200673
[TBL] [Abstract][Full Text] [Related]
30. Myositis and myasthenia during nivolumab administration for advanced lung cancer: a case report and review of the literature.
Veccia A; Kinspergher S; Grego E; Peterlana D; Berti A; Tranquillini E; Caffo O
Anticancer Drugs; 2020 Jun; 31(5):540-544. PubMed ID: 32011360
[TBL] [Abstract][Full Text] [Related]
31. Cascade of immunologic adverse events related to pembrolizumab treatment.
Dhenin A; Samartzi V; Lejeune S; Seront E
BMJ Case Rep; 2019 Jun; 12(6):. PubMed ID: 31167767
[TBL] [Abstract][Full Text] [Related]
32. Myositis as a neuromuscular complication of immune checkpoint inhibitors.
Vermeulen L; Depuydt CE; Weckx P; Bechter O; Van Damme P; Thal DR; Claeys KG
Acta Neurol Belg; 2020 Apr; 120(2):355-364. PubMed ID: 31993961
[TBL] [Abstract][Full Text] [Related]
33. Anti-Kv1.4 Antibody-positive Nivolumab-induced Myasthenia Gravis and Myositis Presenting with Bilateral Ptosis and Demonstrating Different Pathophysiologies.
Kitazaki Y; Yamamura O; Usui K; Ueno A; Sanada S; Sasaki H; Endo Y; Enomoto S; Ikawa M; Nakamoto Y; Hamano T
Intern Med; 2023; 62(20):3013-3020. PubMed ID: 37839874
[TBL] [Abstract][Full Text] [Related]
34. Myasthenia gravis induced by nivolumab in patients with non-small-cell lung cancer: a case report and literature review.
Hasegawa Y; Kawai S; Ota T; Tsukuda H; Fukuoka M
Immunotherapy; 2017 Aug; 9(9):701-707. PubMed ID: 28649876
[TBL] [Abstract][Full Text] [Related]
35. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
[No Abstract] [Full Text] [Related]
36. Immune checkpoint inhibitors (ICIs)-related ocular myositis.
Garibaldi M; Calabrò F; Merlonghi G; Pugliese S; Ceccanti M; Cristiano L; Tartaglione T; Petrucci A
Neuromuscul Disord; 2020 May; 30(5):420-423. PubMed ID: 32387281
[TBL] [Abstract][Full Text] [Related]
37. A case of myositis with dropped head syndrome and anti-titin antibody positivity induced by pembrolizumab.
Takahashi S; Mukohara S; Hatachi S; Yamashita M; Kumagai S
Scand J Rheumatol; 2020 Nov; 49(6):509-511. PubMed ID: 32914675
[No Abstract] [Full Text] [Related]
38. Clinical spectrum of neuromuscular complications after immune checkpoint inhibition.
Puwanant A; Isfort M; Lacomis D; Živković SA
Neuromuscul Disord; 2019 Feb; 29(2):127-133. PubMed ID: 30638612
[TBL] [Abstract][Full Text] [Related]
39. [Re-Administration of Pembrolizumab for Urothelial Carcinoma after immune-Related Myasthenia Gravis : A Case Report].
Kurokawa M; Shimizu K; Kitabayashi R; Ogawa K; Okada Y; Kubo K; Yamaguchi D; Okubo K
Hinyokika Kiyo; 2022 Sep; 68(9):295-300. PubMed ID: 36199208
[TBL] [Abstract][Full Text] [Related]
40. Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies.
Fazal M; Prentice DA; Kho LK; Fysh E
Intern Med J; 2020 Aug; 50(8):1003-1006. PubMed ID: 33306231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]